Table 1.
Summary of laboratory data
| Patient 1 | Patient 2 | |
|---|---|---|
| Age (y) | 68 | 67 |
| Hypertension (y/n) | n | y |
| Diabetes (y/n) | y | n |
| RAS blockade (y/n) | n | y |
| Prior oncological treatment | 7 lines | 8 lines |
| Past platinum chemotherapy exposure (y/n) | y | n |
| Baseline Scr (mg/dl) | 1.6 | 1.2 |
| Baseline eGFR (ml/min per 1.73 m2) | 44 | 64 |
| Scr at cessation of 225Ac-PSMA617 | 2.7 | 1.8 |
| Scr at last follow-up | 3.0 | 1.9 |
| eGFR at last follow-up (ml/min per 1.73 m2) | 20 | 35 |
eGFR, estimated glomerular filtration rate; PSMA, prostate-specific membrane antigen; RAS, renin-angiotensin system; Scr, serum creatinine; y/n, yes/no; 225Ac, actinium-225.